Capricor Therapeutics (NASDAQ:CAPR) shares plummeted more than 26% after it reported the US Food and Drug Administration (FDA) has not approved its Biologics License Application for deramiocel, the company's lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). In a Complete Response Letter to Capricor, the FDA stated that the application did not meet the statutory requirement for substantial evidence of effectiveness and requested additional clinical data before reconsidering approval.

VCTR's AUM rose 3.2% in June, driven by strong gains across equity, solutions, and fixed-income categories.

Assurant rides on growth in capital-light businesses, Connected Living, and Global Housing, supported by solid cash flow and strategic capital deployment.

UK banks have had their fair share of in-flight turbulence, but analysts still see them heading for a stable landing. According to UBS, domestic lenders have largely closed the gap with their European peers in terms of valuation, and the outlook remains constructive despite some short-term headwinds.

Wells Fargo gains flexibility, but can it edge past JPMorgan's scale and IB dominance? Let's explore how capital returns, growth plans and valuations stack up.

Cadence Design Systems CDNS stock has rallied 23.8% over the past three months. The stock closed last trading session at $322.66 and is now closer to its 52-week high of $330.09.

Palo Alto Networks' FCF margin rose to 25.3% in Q3 as AI platforms drive scale and multi-product deals build long-term momentum.

NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to six classes of mortgage-backed certificates from Angel Oak Mortgage Trust 2025-8 (AOMT 2025-8), a $271.3 million non-prime RMBS transaction. The underlying collateral, comprised of 550 residential mortgages, is characterized by a significant concentration of loans underwritten using alternative income documentation. All the loans are either classified as non-qualified mortgages (46.3%) or exempt (53.7%) from the Ability-to-Repay/Qua.

APPROXIMATELY 70 EXCEPTIONAL COLLECTOR CARS WILL BE AUCTIONED ON OCTOBER 31 AT WYNN LAS VEGAS APPROXIMATELY 70 EXCEPTIONAL COLLECTOR CARS WILL BE AUCTIONED ON OCTOBER 31 AT WYNN LAS VEGAS

There's already a robotics revolution underway, which has been marketed as an AI revolution. Today, I will elaborate on this train of thought and detail how Nvidia Corporation has already built the robotic offices of the 21st century. While Nvidia is now a behemoth business at $4T, I still believe there's room for share price appreciation through a combination of organic growth and share buybacks.

The chip maker sells the basic building-block chips that go into products in nearly every sector of the economy, from autos and industrials to consumer electronics.

Key Points in This Article: Quantum computing's potential to transform industries like cryptography and drug discovery is driving a projected $850 billion market by 2040, reshaping the technological landscape.

BigBear.ai Holdings, Inc. BBAI has been on a tear, with its stock surging nearly 86% over the past month. This sharp rally far outpaces the broader market, where the S&P 500 rose just 3.5%, the Zacks Computer and Technology sector added 5.5%, and the Zacks Computers – IT Services industry actually declined 0.4%.

European Wax Center's digital-first marketing revamp is showing early gains as it eyes stronger traffic and sales in late 2025.

NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.

PSMT Q3 net merchandise sales up 8% year over year. The company is weighing Chile as a market for multiple new warehouse clubs.

EADSY, VRTS and IBKR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 11, 2025.

Delta's upbeat forecast lifts JETS 7.3% and AIRL 7.9%, reviving airline ETFs after a rough stretch for the sector.

AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.